Astria Therapeutics Inc (NASDAQ: ATXS) is -16.11% lower on its value in year-to-date trading and has touched a low of $6.95 and a high of $16.90 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The ATXS stock was last observed hovering at around $7.75 in the last trading session, with the day’s loss setting it -0.25%.
Currently trading at $7.50, the stock is -13.03% and -22.09% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.24 million and changing -3.23% at the moment leaves the stock -27.49% off its SMA200. ATXS registered -0.79% loss for a year compared to 6-month loss of -32.13%. The firm has a 50-day simple moving average (SMA 50) of $9.626 and a 200-day simple moving average (SMA200) of $10.343975.
The stock witnessed a -22.44% gain in the last 1 month and extending the period to 3 months gives it a -35.12%, and is 0.67% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 5.64% over the week and 5.18% over the month.
Astria Therapeutics Inc (ATXS) has around 59 employees, a market worth around $423.26M and $0.00M in sales. Distance from 52-week low is 7.84% and -55.62% from its 52-week high. The company has generated returns on investments over the last 12 months (-28.92%).
The EPS is expected to grow by 29.91% this year, but quarterly earnings will post 0.00% year-over-year. Quarterly sales are estimated to shrink 0.00% in year-over-year returns.
Astria Therapeutics Inc (ATXS) Top Institutional Holders
164.0 institutions hold shares in Astria Therapeutics Inc (ATXS), with institutional investors hold 107.27% of the company’s shares. The shares outstanding are 56.43M, and float is at 45.38M with Short Float at 7.42%. Institutions hold 106.77% of the Float.
The top institutional shareholder in the company is PERCEPTIVE ADVISORS LLC with over 6.49 million shares valued at $59.02 million. The investor’s holdings represent 12.4017% of the ATXS Shares outstanding. As of 2024-06-30, the second largest holder is FMR LLC with 6.05 million shares valued at $55.1 million to account for 11.5778 of the shares outstanding. The other top investors are RA CAPITAL MANAGEMENT, L.P. which holds 5.04 million shares representing 9.6449% and valued at over $45.9 million, while VR ADVISER, LLC holds 6.9006 of the shares totaling 3.61 million with a market value of $32.84 million.
Astria Therapeutics Inc (ATXS) Insider Activity
The most recent transaction is an insider sale by Morabito Christopher, the company’s Chief Medical Officer. SEC filings show that Morabito Christopher sold 10,000 shares of the company’s common stock on Apr 01 ’24 at a price of $13.59 per share for a total of $0.14 million. Following the sale, the insider now owns 0.0 shares.
Astria Therapeutics Inc disclosed in a document filed with the SEC on Feb 01 ’24 that PERCEPTIVE ADVISORS LLC (Director) bought a total of 2,481,350 shares of the company’s common stock. The trade occurred on Feb 01 ’24 and was made at $12.09 per share for $30.0 million. Following the transaction, the insider now directly holds 4.87 million shares of the ATXS stock.
Still, SEC filings show that on Jan 29 ’24, Morabito Christopher (Chief Medical Officer) disposed off 9,200 shares at an average price of $11.15 for $0.1 million. The insider now directly holds 0 shares of Astria Therapeutics Inc (ATXS).
